2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2013
Comparison of BMI and Physical Activity Between Old Order Amish Children and Non-Amish Children
Hairston KG, Ducharme JL, Treuth MS, Hsueh WC, Jastreboff AM, Ryan KA, Shi X, Mitchell BD, Shuldiner AR, Snitker S. Comparison of BMI and Physical Activity Between Old Order Amish Children and Non-Amish Children. Diabetes Care 2013, 36: 873-878. PMID: 23093661, PMCID: PMC3609522, DOI: 10.2337/dc12-0934.Peer-Reviewed Original ResearchConceptsMin/dayPhysical activityOld Order AmishNutrition Examination Survey dataBMI z-scoreVigorous physical activityComparison of BMIHip-worn accelerometersOld Order Amish childrenNon-Hispanic white populationPediatric overweightMean BMIExcess weightNational HealthLong-term protectionLow prevalenceES groupNHANES estimatesChildhood factorsZ-scorePA levelsBMIDiabetesAnthropometric dataWhite population